(Q38466427)

3 September 2017

title

Cost-effectiveness of statin therapy for vascular event prevention in adults with elevated C-reactive protein: implications of JUPITER (English)

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.516994

9 July 2024

1 reference

Julia F. Slejko

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20828360

9 July 2024

Robert L. Page

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20828360

9 July 2024

Patrick W. Sullivan

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20828360

9 July 2024

language of work or name

English

0 references

publication date

1 October 2010

1 reference

full work available at URL

3 September 2017

http://www.tandfonline.com/doi/pdf/10.1185/03007995.2010.516994

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.516994

Current Medical Research and Opinion

9 July 2024

published in

1 reference

3 September 2017

volume

26

1 reference

3 September 2017

issue

10

1 reference

3 September 2017

page(s)

2485-2497

1 reference

Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

3 September 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.516994

Atherosclerosis — An Inflammatory Disease

9 July 2024

3

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.516994

C-reactive protein in the prediction of cardiovascular events

9 July 2024

4

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.516994

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

9 July 2024

5

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.516994

Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol

9 July 2024

6

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.516994

Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors

9 July 2024

7

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.516994

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

9 July 2024

8

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.516994

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

9 July 2024

9

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.516994

Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective

9 July 2024

10

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.516994

Statin cost-effectiveness comparisons using real-world effectiveness data: formulary implications

9 July 2024

11

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.516994

Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis

9 July 2024

12

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.516994

Cost-effectiveness of treatments reducing coronary heart disease mortality in Ireland, 2000 to 2010.

9 July 2024

14

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.516994

Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease

9 July 2024

15

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.516994

Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people

9 July 2024

16

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.516994

Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.

9 July 2024

17

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.516994

Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men.

9 July 2024

18

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.516994

Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia

9 July 2024

19

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.516994

Statin cost-effectiveness in the United States for people at different vascular risk levels

9 July 2024

20

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.516994

Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering

9 July 2024

21

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.516994

The Jupiter trial: key findings, controversies, and implications

9 July 2024

22

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.516994

From here to JUPITER: identifying new patients for statin therapy using data from the 1999-2004 National Health and Nutrition Examination Survey

9 July 2024

24

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.516994

An introduction to Markov modelling for economic evaluation

9 July 2024

25

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.516994

Long-term survival and causes of death after stroke

9 July 2024

26

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.516994

Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project.

9 July 2024

27

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.516994

Statin safety: a systematic review

9 July 2024

28

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.516994

Approximate equivalent rosuvastatin doses for temporary statin interchange programs

9 July 2024

29

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.516994

Sample Selection Bias as a Specification Error

9 July 2024

33

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.516994

Preference-Based EQ-5D index scores for chronic conditions in the United States

9 July 2024

35

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.516994

A national catalog of preference-based scores for chronic conditions in the United States

9 July 2024

36

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.516994

Handling uncertainty in cost-effectiveness models

9 July 2024

37

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.516994

Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease

9 July 2024

38

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.516994

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

9 July 2024

39

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.516994

Non-adherence to statin therapy: a major challenge for preventive cardiology

9 July 2024

41

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.516994

Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction

9 July 2024

42

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.516994

Impact of medication therapy discontinuation on mortality after myocardial infarction

9 July 2024

43

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.516994

2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations

9 July 2024

44

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.516994

Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastat

9 July 2024

45

1 reference

https://api.crossref.org/works/10.1185/03007995.2010.516994

9 July 2024

Identifiers

1 reference

release_d5se2sngdjaq3lc4aff3nzty3e

3 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/d5se2sngdjaq3lc4aff3nzty3e

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference